Chirurgisches Outcome bei Colitis ulcerosa in der Biologika-ÄraSurgical outcome for ulcerative colitis patients in the era of biologics

[1] Kirchgesner J(2017)Therapeutic management of inflammatory bowel disease in real-life practice in the current era of antiTNF agents: analysis of the French administrative health database 2009–2014 Aliment Pharmacol Ther 45 37-49

[2] Lemaitre M(2018)The current state of the art for biological therapies and new small molecules in inflammatory bowel disease Mucosal Immunol 11 1558-1570

[3] Rudnichi A(2008)Infliximab in ulcerative colitis is associated with an increased risk of postoperative complications after restorative proctocolectomy Dis Colon Rectum 51 1202-1207

[4] Racine A(2007)Effect of infliximab on short-term complications in patients undergoing operation for chronic ulcerative colitis J Am Coll Surg 204 956-962

[5] Zureik M(2011)Minimally invasive pouch surgery for ulcerative colitis: is there a benefit in staging? Dis Colon Rectum 54 306-310

[6] Carbonell F(2013)Possible overuse of 3‑stage procedures for active ulcerative colitis JAMA Surg 148 658-664

[7] Dray-Spira R(2009)Corticosteroids but not infliximab increase short-term postoperative infectious complications in patients with ulcerative colitis Inflamm Bowel Dis 15 1062-1070

[8] Paramsothy S(2014)Initial surgical management of ulcerative colitis in the biologic era Dis Colon Rectum 57 1358-1363

[9] Rosenstein AK(2015)National trends of 3‑ versus 2‑stage restorative proctocolectomy for chronic ulcerative colitis Dis Colon Rectum 58 199-204

[10] Mehandru S(2013)Meta-analysis: peri-operative anti-TNFa treatment and post-operative complications in patients with inflammatory bowel disease Aliment Pharmacol Ther 37 1057-1064

[1] Kirchgesner J(2017)Therapeutic management of inflammatory bowel disease in real-life practice in the current era of antiTNF agents: analysis of the French administrative health database 2009–2014 Aliment Pharmacol Ther 45 37-49

[2] Lemaitre M(2018)The current state of the art for biological therapies and new small molecules in inflammatory bowel disease Mucosal Immunol 11 1558-1570

[3] Rudnichi A(2008)Infliximab in ulcerative colitis is associated with an increased risk of postoperative complications after restorative proctocolectomy Dis Colon Rectum 51 1202-1207

[4] Racine A(2007)Effect of infliximab on short-term complications in patients undergoing operation for chronic ulcerative colitis J Am Coll Surg 204 956-962

[5] Zureik M(2011)Minimally invasive pouch surgery for ulcerative colitis: is there a benefit in staging? Dis Colon Rectum 54 306-310

[6] Carbonell F(2013)Possible overuse of 3‑stage procedures for active ulcerative colitis JAMA Surg 148 658-664

[7] Dray-Spira R(2009)Corticosteroids but not infliximab increase short-term postoperative infectious complications in patients with ulcerative colitis Inflamm Bowel Dis 15 1062-1070

[8] Paramsothy S(2014)Initial surgical management of ulcerative colitis in the biologic era Dis Colon Rectum 57 1358-1363

[9] Rosenstein AK(2015)National trends of 3‑ versus 2‑stage restorative proctocolectomy for chronic ulcerative colitis Dis Colon Rectum 58 199-204

[10] Mehandru S(2013)Meta-analysis: peri-operative anti-TNFa treatment and post-operative complications in patients with inflammatory bowel disease Aliment Pharmacol Ther 37 1057-1064